NEOK is attending several upcoming conferences. @Oppenheimer, @GoldmanSachs, @Stifel, @Jefferies, & @UBS Heading to any of these events? Let’s connect! #Biotech #LifeSciences #HealthcareInnovation

NEOK Bio’s CEO, Mayank Gandhi, M.D., recently joined @dslevine on #TheBioReportPodcast to discuss the current challenges, potential, and future of antibody-drug conjugates (ADCs) in the treatment of solid tumors. Listen here: bit.ly/46yOeUU #ADC #MedEd

NEOK Bio CEO Mayank Gandhi shares his perspective in @PharmaVoice on reducing delays and accelerating access for clinical trials in the U.S. Read more: bit.ly/4zsmte6 #ADC #ClinicalTrials #Biopharma #DrugDevelopment #MedEd

NEOK Bio’s CEO, Mayank Gandhi, M.D., recently joined @KarenJagoda on the Empowered Patient Podcast to discuss how bispecific #AntibodyDrugConjugates could address some of the most pressing challenges in solid tumors. Listen here: bit.ly/4oNHzid #ADC #MedEd

NEOK Bio has dosed the first patients in Phase 1 trials for NEOK001 and NEOK002, our lead bispecific ADC candidates targeting difficult-to-treat solid tumors. Read more: bit.ly/4f5oK7f #ADCs #AntibodyDrugConjugates #CancerResearch #Innovation #Biotech #MedEd

NEOK Bio is heading to @CHI_Healthtech's 2026 #PEGSummit! Hear from our CEO, Mayank Gandhi, on the development of our dual‑targeting #BispecificADC strategy. View the program: bit.ly/48WawSi #AntibodyDrugConjugates #OncologyInnovation #Biotech #DrugDevelopment #MedEd

We’re excited to present new research at this year’s @AACR Annual Meeting. If you’re going to be at #AACR2026, come see our poster and meet the team! Learn more: bit.ly/41FMmrg #ADC #AntibodyDrugConjugates #CancerResearch #OncologyInnovation #MedEd

NEOK Bio is proud to announce the @US_FDA has granted Investigational New Drug (IND) clearance for NEOK002, our Novel Bispecific ADC Targeting EGFR and MUC1 in solid tumors. Learn more: bit.ly/46Cskk9 #IND #ADC #Oncology

#NEWS: The @US_FDA accepted our IND application for NEOK001. This approval will allow us to start a Phase 1 clinical trial and be our first program to enter clinical development. Learn more: bit.ly/4qCBPaU #IND #ADC #oncology

Save the date: Our CEO, Mayank Gandhi, M.D., presents at #BiotechShowcase in San Francisco, Monday, January 12, 2025, at 1:30 p.m. PST! Connect with us here: bit.ly/3YlSRxK #JPMWeek #Biotech #Leadership

We’re at @SachsAssociates 11th Annual Oncology Innovation Forum! CEO Mayank Gandhi, M.D., joins a panel on Next-Gen ADCs & Bispecifics. Later, NEOK Bio presents our vision for better cancer outcomes. #Sachs_OIF #Leadership #ADC #Biotech

NEOK BIO launches with $75 million financing to pioneer the future of bispecific antibody drug conjugates in hard-to-treat cancers. Stay tuned for more updates and read the press release here: bit.ly/47FxCer #ADC #drugdevelopment #innovation #oncology #SeriesA